Mary Jean Sparks from Krum, TX, age 70

License Records

Mary Armstead Sparks

License #:

20465 - Expired

Category:

Nursing

Issued Date:

May 18, 1965

Effective Date:

Feb 20, 2007

Expiration Date:

Oct 31, 1966

Type:

Registered Nurse

Us Patents

Gene Disruptions, Compositions And Methods Relating Thereto
view source
US Patent:

7858843, Dec 28, 2010
Filed:

May 18, 2006
Appl. No.:

11/814361
Inventors:

Ling Ling Culbertson - Spring TX, US
Frederic J. de Sauvage - Foster City CA, US
Charles Montgomery - Jay OK, US
Mary Jean Sparks - Magnolia TX, US
Assignee:

Genentech, Inc. - South San Francisco CA
International Classification:

G01N 33/00
C12N 5/06
C12Q 1/02
US Classification:

800 3, 435325, 435354, 435 29
Abstract:

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO69122, PRO204, PRO214, PRO222, PRO234, PRO265, PRO309, PRO332, PRO342, PRO356, PRO540, PRO618, PRO944, PRO994, PRO1079, PRO1110, PRO1122, PRO1138, PRO1190, PRO1272, PRO1286, PRO1295, PRO1309, PRO1316, PRO1383, PRO1384, PRO1431, PRO1434, PRO1475, PRO1481, PRO1568, PRO1573, PRO1599, PRO1604, PRO1605, PRO1693, PRO1753, PRO1755, PRO1777, PRO1788, PRO1864, PRO1925, PRO1926, PRO3566, PRO4330, PRO4423, PRO36935, PRO4977, PRO4979, PRO4980, PRO4981, PRO5801, PRO5995, PRO6001, PRO6095, PRO6182, PRO7170, PRO7171, PRO7436, PRO9912, PRO9917, PRO37337, PRO37496, PRO19646, PRO21718, PRO19820, PRO21201, PRO20026, PRO20110, PRO23203 or PRO35250 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.

Gene Disruptions, Compositions And Methods Relating Thereto
view source
US Patent:

7931902, Apr 26, 2011
Filed:

Jul 18, 2006
Appl. No.:

11/814549
Inventors:

Frederic J. de Sauvage - Foster City CA, US
Gretchen Frantz - San Francisco CA, US
Charles Montgomery - Jay OK, US
Franklin Peale - San Carlos CA, US
Mary Jean Sparks - Magnolia TX, US
Assignee:

Genentech, Inc. - South San Francisco CA
International Classification:

A01K 67/00
A61K 39/395
A61P 43/00
US Classification:

4241721, 800 3, 800 13, 800 9
Abstract:

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO226, PRO257, PRO268, PRO290, PRO36006, PRO363, PRO365, PRO382, PRO444, PRO705, PRO1071, PRO1125, PRO1134, PRO1155, PRO1281, PRO1343, PRO1379, PRO1380, PRO1387, PRO1419, PRO1433, PRO1474, PRO1550, PRO1571, PRO1572, PRO1759, PRO1904, PRO35193, PRO4341, PRO4348, PRO4369, PRO4381, PRO4407, PRO4425, PRO4985, PRO4989, PRO5737, PRO5800, PRO5993, PRO6017, PRO7174, PRO9744, PRO9821, PRO9852, PRO9873, PRO10196, PRO34778, PRO20233, PRO21956, PRO57290, PRO38465, PRO38683 or PRO85161 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.

Gene Disruptions, Compositions And Methods Relating Thereto
view source
US Patent:

7947866, May 24, 2011
Filed:

Oct 18, 2005
Appl. No.:

11/577547
Inventors:

Mary Jean Sparks - Magnolia TX, US
Assignee:

Genentech, Inc. - South San Francisco CA
International Classification:

G01N 33/00
US Classification:

800 3, 800 11, 800 18
Abstract:

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO194, PRO220, PRO241, PRO284, PRO331, PRO354, PRO355, PRO533, PRO541, PRO725, PRO937, PRO1014, PRO1120, PRO1182, PRO1325, PRO1382, PRO1410, PRO1555, PRO1556, PRO1760, PRO1787, PRO1868, PRO4326, PRO4332, PRO4346, PRO4400, PRO6003, PRO6094, PRO6244, PRO9820, PRO9828, PRO10274, PRO16090, PRO19644, PRO21340, PRO92165, PRO85143, PRO1124, PRO1026 or PRO23370 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.

Gene Disruptions, Compositions And Methods Relating Thereto
view source
US Patent:

7956237, Jun 7, 2011
Filed:

Aug 23, 2005
Appl. No.:

11/572702
Inventors:

Charles Montgomery - Jay OK, US
Mary Jean Sparks - Magnolia TX, US
Assignee:

Genentech, Inc. - South San Francisco CA
International Classification:

G01N 33/00
A01K 67/027
US Classification:

800 3, 800 18
Abstract:

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO196, PRO217, PRO231, PRO236, PRO245, PRO246, PRO258, PRO287, PRO328, PRO344, PRO357, PRO526, PRO724, PRO731, PRO732, PRO1003, PRO1104, PRO1151, PRO1244, PRO1298, PRO1313, PRO1570, PRO1886, PRO1891, PRO4409, PRO5725, PRO5994, PRO6097, PRO7425, PRO10102, PRO10282, PRO61709 or PRO779 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.

Methods Of Identifying Agents That Ameliorate Or Modulate Effects Of Pro1328 Gene Disruptions
view source
US Patent:

8227661, Jul 24, 2012
Filed:

Oct 19, 2010
Appl. No.:

12/907655
Inventors:

Joel A. Edwards - Las Flores CA, US
Wenhu Huang - San Digeo CA, US
Charles Montgomery - Jay OK, US
Ni Nancy Qian - San Diego CA, US
Mary Jean Sparks - Magnolia TX, US
Peter Vogel - The Woodlands TX, US
Mindy Oox - Houston TX, US
Assignee:

Lexicon Genetics, Inc. - The Woodlands TX
International Classification:

G01N 33/00
A01K 67/00
A01K 67/027
US Classification:

800 3, 800 8, 800 9, 800 18
Abstract:

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO227, PRO233, PRO238, PRO1328, PRO4342, PRO7423, PRO10096, PRO21384, PRO353 or PRO1885 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.

Gene Disruptions, Compositions And Methods Relating Thereto
view source
US Patent:

8207396, Jun 26, 2012
Filed:

Feb 18, 2011
Appl. No.:

13/031009
Inventors:

Bobby Joe Payne - The Woodlands TX, US
Mary Jean Sparks - Magnolia TX, US
Wen Xiong - Tomball TX, US
Assignee:

Genentech, Inc. - South San Francisco CA
International Classification:

G01N 33/00
US Classification:

800 3
Abstract:

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO226, PRO257, PRO268, PRO290, PRO36006, PRO363, PRO365, PRO382, PRO444, PRO705, PRO1071, PRO1125, PRO1134, PRO1155, PRO1281, PRO1343, PRO1379, PRO1380, PRO1387, PRO1419, PRO1433, PRO1474, PRO1550, PRO1571, PRO1572, PRO1759, PRO1904, PRO35193, PRO4341, PRO4348, PRO4369, PRO4381, PRO4407, PRO4425, PRO4985, PRO4989, PRO5737, PRO5800, PRO5993, PRO6017, PRO7174, PRO9744, PRO9821, PRO9852, PRO9873, PRO10196, PRO34778, PRO20233, PRO21956, PRO57290, PRO38465, PRO38683 or PRO85161 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.

Novel Gene Disruptions, Compositions And Methods Relating Thereto
view source
US Patent:

20070292438, Dec 20, 2007
Filed:

Dec 13, 2004
Appl. No.:

10/583466
Inventors:

Stephen Anderson - The Woodlands TX, US
Jane Brennan - Lothian Region, GB
Frederic de Sauvage - Foster City CA, US
Zhiyong Ding - Longmont CO, US
Joel Edwards - The Woodlands TX, US
Nelda Fikes - Spring TX, US
Wenhu Huang - San Diego CA, US
Wenjun Ouyang - Foster City CA, US
Carolina Rangel - Houston TX, US
Mamta Sangha - Tualatin OR, US
Mary Sparks - Magnolia TX, US
Joseph Trackey - The Woodlands TX, US
Melissa Vetter - Spring TX, US
Ching-Yun Wang - The Woodlands TX, US
Jessica Woodings - Longmont CO, US
International Classification:

A61K 39/395
C07K 16/00
C12N 5/00
C12N 5/06
C12Q 1/02
G01N 33/00
US Classification:

424172100, 435029000, 435325000, 435352000, 435375000, 530387100, 800003000
Abstract:

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO224, PRO9783, PRO1108, PRO34000, PRO240, PRO943, hu A33, PRO230, PRO178, PRO1199, PRO4333, PRO1336, PRO19598, PRO1083, hu TRPM2 or PRO1801 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.

Genetically Engineered And Phenotyped Mice And Stem Cell Clones For Producing The Same
view source
US Patent:

20080189799, Aug 7, 2008
Filed:

Oct 26, 2007
Appl. No.:

11/978234
Inventors:

Liangfen Fan - Spring TX, US
Glenn Friedrich - Houston TX, US
Laurie Jeanette Minze - Katy TX, US
Charles Montgomery - Jay OK, US
Bobby Joe Payne - The Woodlands TX, US
Carolina Rangel - Houston TX, US
Arthur T. Sands - The Woodlands TX, US
Tracy Ellen Willis Sevaux - Conroe TX, US
Mary Jean Sparks - Magnolia TX, US
Peter Vogel - The Woodlands TX, US
Brian Zambrowicz - The Woodlands TX, US
International Classification:

C12N 15/11
A01K 67/027
US Classification:

800 6, 800 18
Abstract:

The current invention relates to genetically engineered mice, cells derived from those mice, and polynucleotides and polypeptides corresponding to genes affected by the engineered mutation. The invention also relates to antibodies raised in a mouse of the invention. The invention further provides methods for using the mice, cells, polynucleotides, polypeptides and antibodies of the invention.

Name / Title

Company / Classification

Phones & Addresses

Mary N. Sparks
President, Director

THE HOUSTON HEIGHTS WOMAN'S CLUB

1846 Harvard St, Houston, TX 77008

Mary Jean Sparks
Director

CLASSIC ANTIQUE RESTORATION SERVICE INC

206A S Loop 336 W, Conroe, TX 77304
1205 Goodson Rd, Magnolia, TX 77355
7218 Black Frst Dr, Magnolia, TX 77354

Mary Sparks
VP, Director

DALLAS TEEN AGE INC

765 Oak Holw, Longview, TX 75607
765 Oak Holw Ln, Lewisville, TX 75077

Mary Sparks
MM

CRUSHED CONCRETE & ASPHALT LLC

6915 Brittmoore Rd, Houston, TX 77041
6915 Britmoore Rd, Houston, TX 77041

Medicine Doctors

Mary J. Monari Sparks

view source

Specialties:

Internal Medicine

Work:

Cooper University Physicians Internal Medicine
1103 Kings Hwy N STE 203, Cherry Hill, NJ 08034
(856)3211919 (phone), (856)3210206 (fax)

Education:

Medical School
Hahnemann University School of Medicine
Graduated: 1998

Procedures:

Allergen Immunotherapy
Arthrocentesis
Electrocardiogram (EKG or ECG)
Pulmonary Function Tests
Vaccine Administration

Conditions:

Acute Pharyngitis
Attention Deficit Disorder (ADD)
Disorders of Lipoid Metabolism
Gastroesophageal Reflux Disease (GERD)
Hypothyroidism

Languages:

English
Spanish

Description:

Dr. Monari Sparks graduated from the Hahnemann University School of Medicine in 1998. She works in Cherry Hill, NJ and specializes in Internal Medicine. Dr. Monari Sparks is affiliated with Cooper University Hospital.